United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

by · The Cerbat Gem

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Benkowitz also recently made the following trade(s):

  • On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total transaction of $10,768,050.00.
  • On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00.
  • On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $473.66, for a total transaction of $10,657,350.00.
  • On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00.
  • On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total transaction of $10,171,575.00.
  • On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00.
  • On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00.
  • On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $427.41, for a total value of $9,616,725.00.
  • On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00.
  • On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $500.00 on Wednesday. The stock has a fifty day moving average price of $459.61 and a two-hundred day moving average price of $377.40. The stock has a market capitalization of $21.53 billion, a price-to-earnings ratio of 18.95, a PEG ratio of 4.97 and a beta of 0.86. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $502.77.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the previous year, the firm earned $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. HighTower Advisors LLC increased its position in United Therapeutics by 8.1% during the first quarter. HighTower Advisors LLC now owns 20,362 shares of the biotechnology company’s stock worth $6,277,000 after buying an additional 1,530 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 0.7% in the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after acquiring an additional 4,145 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of United Therapeutics by 0.4% during the first quarter. American Century Companies Inc. now owns 38,320 shares of the biotechnology company’s stock valued at $11,813,000 after acquiring an additional 168 shares during the last quarter. Cresset Asset Management LLC increased its position in United Therapeutics by 1.3% during the 1st quarter. Cresset Asset Management LLC now owns 8,687 shares of the biotechnology company’s stock worth $2,678,000 after purchasing an additional 108 shares in the last quarter. Finally, Raymond James Financial Inc. increased its position in United Therapeutics by 7.3% during the 1st quarter. Raymond James Financial Inc. now owns 55,545 shares of the biotechnology company’s stock worth $17,123,000 after purchasing an additional 3,801 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Jefferies Financial Group restated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Oppenheimer upped their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $505.00.

Get Our Latest Stock Report on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also